Mikhail Blagosklonny is an accomplished researcher, scholar, and professor. He attended the First Pavlov State Medical University in St. Petersburg where he graduated with a Master’s in Internal Medicine and a Doctorate in Cardiology and Medicine. He started his career in New York at the New York Medical College as an associate professor on impactjournals.com. He later moved to the Ordway Research Institute to become a scientist and stayed there for seven years. Mikhail then became an oncology professor at the Roswell Cancer Institute. He holds the position to date. The Institute employed Mikhail because of his revolutionary research and how he could impact cancer treatment. He has proposed novel ways of cancer treatment and prevention. The management at the Institute believes that new anti-cancer treatments could be developed with the resources and the team at the Institute.
Mikhail Blagosklonny’s work has mainly revolved around cancer and therapies that can be used to combat the disease. He has also been involved in the various types of aging mechanisms and drugs that can be used to delay aging. His research led him to work on rapamycin and its relation to anti-aging. He is one of the more vocal backers of the drug as a life extension drug, and he has done the research to prove it. He has worked with Novartis (the pharma company) to try and develop a drug that could ultimately extend life. Mikhail has written theories on cell cyclotherapy, aging, and chemotherapy and how these areas relate to cancer. Mikhail has published over 300 articles which have been cited more than 20,000 times. He has an h-index of 83 which is a measure of the impact that a scholar has in the scientific field. The more citations a scholar receives, the higher an h-index he has.
Mikhail’s work in oncology involves everything to do with cancer. It led him to start Oncotarget on Impact Journals. Oncotarget is a journal that publishes oncology papers weekly and has been instrumental in the progression of cancer research. The paper also publishes articles in fields that relate to cancer including endocrinology and neuroscience. He is the founding Editor of Cell Cycle and is its current Editor-in-Chief. He is an associate editor of Cancer Biology and Therapy. Mikhail has been an associate editor of Autophagy, The American Journal of Pathology, and the International Journal of Cancer. He is a member of the editorial board of Cell Death and Differentiation. This is a board whose members are some of the top scientists and biologists in the world.